Ambarkhane will provide medical leadership and direction in the development of Alligator’s best-in-class preclinical and clinical pipeline
Alligator Bioscience has announced the appointment of Sumeet Ambarkhane, as its Chief Medical Officer. In this role, Ambarkhane will provide medical leadership and direction in the development of Alligator’s best-in-class preclinical and clinical pipeline, including Alligator’s lead assets mitazalimab, a CD40 agonist currently in Phase II clinical development, and ATOR-1017, a 4-1BB agonist in Phase I.
Ambarkhane is a seasoned professional with over 20 years of drug development experience in academia and in the biotechnology and pharmaceutical industries. Ambarkhane has a proven track record of advancing investigational medicines including immunotherapy-biologics, from early phases of development through regulatory approvals and adoption into clinical practice.
Ambarkhane comes to Alligator from MorphoSys, where he served as their Senior Global Program Medical Director. At MorphoSys, he led the clinical development for its hemato-oncology programmes, including tafasitamab (Monjuvi), which was granted breakthrough therapy designation and subsequently an accelerated approval by FDA, in addition to conditional approval by EMA.
Prior to MorphoSys, Ambarkhane spent seven years at UCB Pharmaceuticals, assuming roles of increasing responsibility and across geographies for the company’s immunology and neurology drug development portfolio.
Ambarkhane holds a Bachelor of Medicine, Bachelor of Surgery and Medical Doctorate degrees in medicine and clinical pharmacology from Seth G.S. Medical College and King Edward Memorial Hospital, University of Mumbai in India.
“We are thrilled to welcome a professional of Sumeet’s caliber to the Alligator team,” says Søren Bregenholt, CEO, Alligator Bioscience. “His in-depth expertise in medical science, clinical development, experience from global regulatory submissions, and product registrations will significantly strengthen our efforts to further advance our novel immune-oncology pipeline.”
